To join a breast cancer clinical trial in United States, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in United States directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.

What phases are breast cancer trials in United States?

Active breast cancer trials in United States span Phase 3, Phase 2, Phase 4, Phase 1, Phase 2, Phase 1, Phase 2, Phase 3. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.

Browse More

All United States Trials → Global breast cancer Trials → All Countries → All Trials →

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology

Active Trials in United States (72)

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

High-Resolution Lower Dose Dedicated Breast Computed Tomography (CT)

The Florida ASCENT Study

Study of Aerobic Training for People Receiving Treatment for Breast Cancer

SABER Study for Selected Early Stage Breast Cancer

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

Improving Care for Rural Patients With Solid Tumors

A Study Evaluating the Feasibility and Compliance of Manual Lymphatic Drainage Comparing Indocyanine-Green (ICG) Guided vs. Traditional Guided in Patients Undergoing Axillary Node Dissection for the Treatment of Breast Cancer

EXoPERT EMERALD Clinical Study

A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer

Tirzepatide Weight Loss for MRD+ Early Breast Cancer

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

F-Tryptophan PET/CT in Human Cancers

Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery

High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast Cancer

Near Infrared Spectroscopy (NIRS) as a Method for Measuring Oxidative Capacity of Skeletal Muscle Mitochondria in Breast Cancer and All Gynecological Cancer Patients

Lesion Composition and Quantitative Imaging Analysis on Breast Cancer Diagnosis

EXERT-BCH Exercise Regimen to Improve Muscle Mass After Treatment of Breast Cancer

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

ERAS Protocols in Breast Conserving Surgery

Adaptive Symptom Self-Management Immunotherapy Study

A Study of Pembrolizumab and Cryoablation in People With Breast Cancer

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors

IKS014 in Advanced Solid Tumors That Express HER2

[18F] F-GLN by PET/CT in Breast Cancer

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

Remotely-Delivered Cognitive Behavioral Stress Management for Breast Cancer (R-CBSM)

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Breast Cancer Implementation Science Study With Educational Intervention

ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions

Project SOAR (Speaking Our African American Realities) Awakenings for Black American Women Diagnosed With Breast Cancer

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Factors Associated With Breast Cancer Risks and Outcomes

A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

A Mixed-Methods Metabolomics Investigation of Lifestyle and Energy Balance During Breast Cancer Survivorship

Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing

Combined Immunotherapies in Metastatic ER+ Breast Cancer

Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts

Navigator-Assisted Hypofractionation (NAVAH) on Radiation Therapy Completion in Breast Cancer and Prostate Cancer

Enhancing Mammography Programs for Outreach, Wellness, Education, and Resources (EMPOWER) in Underserved Populations Study

Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS)

Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies

Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria (Mobile Health: Technology and Outcomes in Low and Middle-Income Countries)

Exercise to ReGain Stamina and Energy (The EXERGISE Study)

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

De-convoluting Interactions Between Genes, the Cancer Environment, and the Immune System to Develop Therapies That Work for You

Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab

A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

A Study of a Side Effects and Resource Navigation Program for People With Cancer

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging

Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery

Frequently Asked Questions